{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:24:01Z","timestamp":1762899841670,"version":"build-2065373602"},"reference-count":13,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progr\u00e8s en Urologie"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.purol.2019.11.001","type":"journal-article","created":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T09:31:38Z","timestamp":1574933498000},"page":"35-40","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Tol\u00e9rance de la thermo-chimioth\u00e9rapie par HIVEC\u00ae\u00a0chez les patients r\u00e9fractaires au BCG"],"prefix":"10.1016","volume":"30","author":[{"given":"T.","family":"Marquette","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Walz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Rybikowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Maubon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Branger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Fakhfakh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.L.","family":"Verde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Dermeche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Gravis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Pignot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.purol.2019.11.001_bib0070","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1\u00a0bladder cancer using EORTC risk tables: a combined analysis of 2596\u00a0patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"issue":"12","key":"10.1016\/j.purol.2019.11.001_bib0075","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1016\/j.purol.2018.07.283","article-title":"Recommandations fran\u00e7aises du Comit\u00e9 de Canc\u00e9rologie de l\u2019AFU \u2013 Actualisation 2018-2020\u00a0: tumeurs de la vessie","volume":"28","author":"Roupr\u00eat","year":"2018","journal-title":"Prog Urol"},{"issue":"3","key":"10.1016\/j.purol.2019.11.001_bib0080","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","article-title":"EAU guidelines on non\u2013muscle-invasive urothelial carcinoma of the bladder: update 2016","volume":"71","author":"Babjuk","year":"2017","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.purol.2019.11.001_bib0085","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.eururo.2016.01.006","article-title":"Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin C versus bacillus calmette-gu\u00e9rin for adjuvant treatment of patients with intermediate- and high-risk non\u2013muscle-invasive bladder cancer","volume":"69","author":"Arends","year":"2016","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.purol.2019.11.001_bib0090","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.eururo.2018.09.005","volume":"75","author":"Tan","year":"2019","journal-title":"Eur Urol"},{"issue":"14","key":"10.1016\/j.purol.2019.11.001_bib0095","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.purol.2016.09.057","article-title":"Instillations endov\u00e9sicales dans les tumeurs de vessie n\u2019infiltrant pas le muscle (TVNIM). Perspectives d\u2019utilisation de la thermochimioth\u00e9rapie","volume":"26","author":"Irani","year":"2016","journal-title":"Prog Urol"},{"journal-title":"Published: November 27, 2017. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES. National Institutes of Health Published: November 27","article-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0","year":"2017","key":"10.1016\/j.purol.2019.11.001_bib0100"},{"issue":"3","key":"10.1016\/j.purol.2019.11.001_bib0105","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3109\/02656736.2014.900194","article-title":"A clinical trial of neoadjuvant hyperthermic intravesical chemotherapy (HIVEC) for treating intermediate and high-risk non-muscle invasive bladder cancer","volume":"30","author":"Sousa","year":"2014","journal-title":"Int J Hyperthermia"},{"issue":"4","key":"10.1016\/j.purol.2019.11.001_bib0110","doi-asserted-by":"crossref","first-page":"374","DOI":"10.3109\/02656736.2016.1142618","article-title":"Recirculant hyperthermic IntraVEsical chemotherapy (HIVEC) in intermediate\u2013high-risk non-muscle-invasive bladder cancer","volume":"32","author":"Sousa","year":"2016","journal-title":"Int J Hyperthermia"},{"issue":"4","key":"10.1016\/j.purol.2019.11.001_bib0115","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3233\/BLC-180191","article-title":"Hyperthermic Intravesical Chemotherapy for BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients","volume":"4","author":"de Jong","year":"2018","journal-title":"Bladder Cancer"},{"issue":"suppl 8","key":"10.1016\/j.purol.2019.11.001_bib0120","first-page":"303","article-title":"Pembrolizumab for high-risk non\u2013muscle invasive bladder cancer unresponsive to bacillus Calmette-Gu\u00e9rin: results from an interim analysis of KEYNOTE-057","volume":"29","author":"De Wit","year":"2018","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.purol.2019.11.001_bib0125","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.prp.2017.07.026","article-title":"Cytological and histological changes in the urothelium produced by electromotive drug administration (EMDA) and by the combination of intravescical hyperthermia and chemotherapy (thermochemotherapy)","volume":"213","author":"Pierconti","year":"2017","journal-title":"Pathol Res Pract"},{"issue":"3","key":"10.1016\/j.purol.2019.11.001_bib0065","doi-asserted-by":"crossref","first-page":"e1150","DOI":"10.1016\/S1569-9056(17)30717-0","article-title":"Safety and tolerability analysis of hyperthermic intravesical mitomycin to mitomycin alone in HIVEC I and HIVEC II: an interim analysis of 307\u00a0patients","volume":"16","author":"Tan","year":"2017","journal-title":"Eur Urol Suppl"}],"container-title":["Progr\u00e8s en Urologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1166708719306098?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1166708719306098?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T06:32:27Z","timestamp":1761114747000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1166708719306098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S1166708719306098"],"URL":"https:\/\/doi.org\/10.1016\/j.purol.2019.11.001","relation":{},"ISSN":["1166-7087"],"issn-type":[{"type":"print","value":"1166-7087"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tol\u00e9rance de la thermo-chimioth\u00e9rapie par HIVEC\u00ae\u00a0chez les patients r\u00e9fractaires au BCG","name":"articletitle","label":"Article Title"},{"value":"Progr\u00e8s en Urologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.purol.2019.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}